Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION study

被引：0
|
作者：
Ashina, M. [1 ]
Roos, C. [2 ]
Ayer, D. W. [3 ]
Ruff, D. [3 ]
Krege, J. H. [3 ]
Li, L. Q. [3 ]
Komori, M. [4 ]
机构：
[1] Univ Copenhagen, Danish Headache Ctr, Rigshosp Glostrup, Copenhagen, Denmark
[2] Hop Lariboisiere, AP HP, Paris, France
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Eli Lilly & Co, Kobe, Hyogo, Japan
来源：
HEADACHE | 2022年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-129
引用
收藏
页码：113 / 114
页数：2
相关论文
共 50 条
  • [1] Long-Term Treatment With Lasmiditan in Patients With Migraine: Results From the Open-Label Extension of the CENTURION Study
    Ashina, M.
    Roos, C.
    Ayer, D.
    Ruff, D.
    Krege, J.
    Li, L. Q.
    Komori, M.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [2] Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial
    Ashina, Messoud
    Roos, Caroline
    Li, Lily Qian
    Komori, Mika
    Ayer, David
    Ruff, Dustin
    Krege, John Henry
    [J]. CEPHALALGIA, 2023, 43 (04)
  • [3] Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial
    Komori, Mika
    Ozeki, Akichika
    Tanji, Yuka
    Kamiki, Eriko
    Krege, John H.
    Li, Lily Qian
    Suzuki, Shiho
    Shibata, Mamoru
    Takeshima, Takao
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25 (01):
  • [4] Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study
    Pozo-Rosich, Patricia
    Detke, Holland C.
    Wang, Shufang
    Dolezil, David
    Li, Lily Q.
    Aurora, Sheena K.
    Reuter, Uwe
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (05) : 731 - 742
  • [5] Long-term treatment with zonisamide: Results of a 2 year open-label extension study
    Wroe, S.
    Duncan, R.
    [J]. EPILEPSIA, 2006, 47 : 138 - 138
  • [6] Rapid Responders to Frovatriptan in Acute Migraine Treatment: Results from a Long-Term, Open-Label Study
    Spierings, Egilius L. H.
    Keywood, Charlotte
    [J]. PAIN MEDICINE, 2009, 10 (04) : 633 - 638
  • [7] Long-term treatment with lumasiran: final results from the phase 2 open-label extension study
    Frishberg, Yaacov
    Groothoff, Jaap W.
    Hulton, Sally-Anne
    Harambat, Jerome
    Hogan, Julien
    Anne-Laure, Sellier-Leclerc
    Hayes, Wesley
    Coenen, Martin
    Willey, Richard
    Gansner, John
    Magen, Daniella
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I2390 - I2392
  • [8] Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)
    Brandes, Jan Lewis
    Klise, Suzanne
    Krege, John H.
    Case, Michael
    Khanna, Rashna
    Vasudeva, Raghavendra
    Raskin, Joel
    Pearlman, Eric M.
    Kudrow, David
    [J]. CEPHALALGIA, 2019, 39 (11) : 1343 - 1357
  • [9] Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
    Tepper, Stewart J.
    Ashina, Messoud
    Reuter, Uwe
    Brandes, Jan Lewis
    Dolezil, David
    Silberstein, Stephen D.
    Winner, Paul
    Zhang, Feng
    Cheng, Sunfa
    Mikol, Daniel D.
    [J]. CEPHALALGIA, 2020, 40 (06) : 543 - 553
  • [10] Long-Term Cardiovascular Safety of Lasmiditan for the Acute Treatment of Migraine for up to One Year: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)
    Rosen, N. L.
    Mathew, P. G.
    Buchanan, A. S.
    Baygani, S.
    Hochstetler, H.
    Khanna, R.
    [J]. HEADACHE, 2020, 60 : 111 - 111
12345